Proston3 gm

Proston is a naturally occurring prostaglandin E2 (PGE2) analog used in obstetric practice, administered only in a hospital or clinical setting under close medical supervision.

Established / FDA-approved uses

• Ripening of an unfavorable cervix in pregnant women at or near term in whom induction of labor is indicated (vaginal insert and endocervical gel formulations)
• Evacuation of the uterus in cases of intrauterine fetal death, missed abortion (up to 28 weeks of gestational age, depending on formulation and local labeling), and non-metastatic gestational trophoblastic disease (hydatidiform mole), where suppository formulations are used

Guideline-supported / adjunct uses

• As part of a planned protocol for induction of labor, often followed by oxytocin administration once adequate cervical ripening has occurred
• Termination of pregnancy in the second trimester (approximately 12 to 20 weeks of gestation), as an alternative to other methods, per local obstetric protocol (suppository formulation)

Proston is never self-administered; it is used exclusively by clinicians experienced in obstetric care, with continuous fetal and maternal monitoring.

Dinoprostone is available in several formulations depending on the clinical indication:

• Vaginal insert (controlled-release), typically containing 10 mg of Dinoprostone in a hydrogel polymer, releasing the drug at approximately 0.3 mg/hour
• Endocervical gel, typically containing 0.5 mg of Dinoprostone per syringe (e.g., 2.5 mL)
• Vaginal gel, such as 0.5 mg Dinoprostone per 3 g gel (as marketed in Bangladesh)
• Vaginal suppository, typically containing 20 mg of Dinoprostone, for second-trimester termination of pregnancy or evacuation of the uterus in missed abortion/fetal death

Proston is a synthetic preparation of naturally occurring prostaglandin E2, a locally acting hormone-like substance that causes softening (ripening), effacement, and dilation of the cervix and stimulates contraction of uterine smooth muscle.

Proston is used in obstetrics to prepare an unfavorable cervix before labor induction, to induce labor at or near term, and, in higher-dose suppository form, to bring about evacuation of the uterine contents in cases such as fetal death in utero, missed abortion, or hydatidiform mole. Because of its powerful uterotonic effect and the risk of excessive uterine contraction (hyperstimulation) with resulting fetal distress or, rarely, uterine rupture, Proston is administered only in a hospital or equivalent monitored obstetric setting, never as a take-home or self-administered medicine.

Proston belongs to the therapeutic class of prostaglandins, specifically classified as a prostaglandin E2 (PGE2) analog / oxytocic and cervical ripening agent used in obstetrics.

Dinoprostone is chemically and pharmacologically identical to naturally occurring prostaglandin E2. It acts locally on the cervix and myometrium through prostaglandin (EP) receptors to:

• Promote dissolution of collagen bundles and increase water content in the cervical connective tissue, leading to softening, effacement, and dilation of the cervix (cervical ripening)
• Stimulate rhythmic contraction of uterine smooth muscle, similar to the contractions of spontaneous labor
• Increase the sensitivity of the myometrium to subsequently administered oxytocin

Following vaginal or endocervical administration, Dinoprostone is absorbed locally and metabolized rapidly, primarily by enzymatic oxidation in most body tissues (particularly lung, liver, and kidney), with a plasma half-life of only a few minutes. Metabolites are excreted mainly in the urine, with a smaller fraction in the feces. The controlled-release vaginal insert is designed to deliver a steady low dose over several hours and can be removed to terminate drug delivery if excessive uterine activity or fetal distress occurs — a notable safety feature not available with orally or systemically administered uterotonics.

• Proston is administered only by trained obstetric personnel in a hospital or equivalent monitored setting.
• Before administration, baseline fetal heart rate and uterine activity are assessed and monitoring is continued throughout use and for a period afterward.
• The vaginal insert, gel, or suppository is placed high in the vagina or cervical canal as appropriate to the formulation; the patient generally remains recumbent for a short period after insertion.
• The controlled-release vaginal insert has a retrieval tape and can be promptly removed if uterine hyperstimulation, fetal distress, or other adverse reactions occur.
• Oxytocin, if subsequently required, is administered only after an appropriate interval following removal of Proston, per protocol, because of the risk of additive uterotonic effect.
• Proston is not an outpatient or take-home medication and must never be self-administered.

Because Proston is used only in a monitored hospital setting, interactions are managed clinically, but the following are clinically significant:

• Oxytocin and other uterotonic agents: Concurrent or closely sequential use with oxytocin or other agents that stimulate uterine contraction can produce additive uterotonic effects, increasing the risk of uterine hyperstimulation/tachysystole; oxytocin administration is delayed for a specified interval after Proston removal/administration per protocol.
• Other prostaglandins (e.g., misoprostol): Should not be used concurrently with Proston, as this increases the risk of excessive uterine activity.
• Nonsteroidal anti-inflammatory drugs (NSAIDs): NSAIDs inhibit prostaglandin synthesis and may theoretically reduce the effectiveness of Proston; concurrent use is generally avoided during induction/ripening.

Common

• Uterine hyperstimulation/tachysystole (excessively frequent or prolonged uterine contractions)
• Nausea, vomiting, and diarrhea
• Fever and chills
• Back pain, headache
• Warm sensation in the vagina (with gel/suppository insertion)

Less common / serious

• Fetal distress or abnormal fetal heart rate patterns associated with uterine hyperstimulation
• Uterine rupture (rare, and associated primarily with risk factors described under Contraindications)
• Amniotic fluid embolism (rare, but a recognized serious risk of any agent that induces strong uterine contractions)
• Hypotension or hypertension
• Postpartum hemorrhage, disseminated intravascular coagulation (rare)

Continuous fetal heart rate and uterine activity monitoring during use of Proston allows early detection of these effects; the vaginal insert can be removed promptly if hyperstimulation or fetal distress occurs.

Pregnancy: Proston is used specifically in pregnancy for cervical ripening, labor induction, or uterine evacuation, and is administered only under close obstetric supervision after a full risk-benefit assessment for the specific clinical situation, respecting the absolute contraindications listed above (see Contraindications and Precautions and Warnings). It is not used in ongoing pregnancies where continuation of the pregnancy is intended, outside of the specific indications for which it is licensed.

Lactation: Proston has a very short plasma half-life and is not intended for repeated or ongoing use once its obstetric indication has been fulfilled (labor/delivery or uterine evacuation). Because of its rapid metabolism and single/short-course clinical use, it is not considered a relevant exposure concern for future breastfeeding; nonetheless, any breastfeeding plans should be discussed with the treating physician in the peripartum period.

• Proston must be used only in a hospital or equivalent facility with continuous fetal heart rate and uterine activity monitoring and immediate access to emergency obstetric intervention, including cesarean delivery.
• Uterine hyperstimulation (tachysystole) can occur and may lead to fetal distress and, rarely, uterine rupture; monitoring allows early detection, and the vaginal insert formulation can be removed promptly to stop further drug delivery if this occurs.
• Use with caution and only after careful risk-benefit assessment in women with active cardiac, pulmonary, renal, or hepatic disease, asthma or a history of bronchospasm, glaucoma or raised intraocular pressure, or a compromised (e.g., scarred) uterus not meeting the absolute contraindication criteria above.
• Gastrointestinal effects (nausea, vomiting, diarrhea) and fever/chills can occur and should be distinguished clinically from signs of infection.
• Proston is not an outpatient or self-administered medication; it must be administered only by, or under direct supervision of, clinicians experienced in labor induction and obstetric emergencies.
• An adequate interval must be observed between Proston removal/administration and subsequent oxytocin administration, per protocol, to reduce the risk of additive uterotonic effects.

Overdose or excessive uterine response to Proston can present as uterine hyperstimulation/tachysystole with abnormal fetal heart rate patterns, and rarely uterine rupture. If overdose or excessive uterine activity is suspected, the vaginal insert (if used) should be removed immediately and the patient should receive urgent obstetric evaluation; supportive measures (e.g., maternal repositioning, oxygen, intravenous fluids, tocolytic therapy) may be required as directed by the treating obstetric team. Because Proston is administered only in a monitored hospital setting, any suspected overdose should prompt immediate medical attention from the attending clinical team rather than any form of home management.

Store in a refrigerator (2°C to 8°C) unless the specific product labeling states otherwise, away from light. Keep out of reach of children. Do not freeze unless the manufacturer's labeling specifically permits it. Always check the storage instructions on the individual product packaging, as requirements can vary by formulation and manufacturer.

Pregnant women

Proston is used exclusively in pregnant women for the specific obstetric indications of cervical ripening, labor induction, or uterine evacuation, under close hospital-based obstetric supervision, respecting the absolute contraindications and precautions described above.

Women with a scarred or previously operated uterus

Use in women with a history of cesarean section or major uterine surgery requires specific individualized risk assessment because of the increased risk of uterine rupture with prostaglandin-induced contractions in a scarred uterus; in many such cases, Proston is avoided altogether (see Contraindications).

Women with cardiac, pulmonary, renal, or hepatic disease

Use requires careful risk-benefit assessment and closer monitoring, as these conditions may be worsened by the hemodynamic or fluid-balance effects associated with labor and uterotonic therapy.

Pediatric and elderly use

Not applicable; Proston is used only in pregnant women of reproductive age.

The duration of Proston use depends on the formulation and indication. The controlled-release vaginal insert is typically left in place for up to 12 hours or removed sooner at the onset of active labor or if hyperstimulation/fetal distress occurs. Endocervical or vaginal gel doses may be repeated after an interval (commonly 6 hours) up to a maximum cumulative dose per product labeling. Vaginal suppositories used for uterine evacuation are typically repeated every 3 to 5 hours for a limited total duration as directed by the treating obstetrician, based on uterine response and clinical monitoring.

Dinoprostone is classified as a prostaglandin E2 (PGE2) analog, within the broader drug class of oxytocic agents / cervical ripening agents used in obstetrics.

Dinoprostone, being structurally and functionally identical to endogenous prostaglandin E2, binds to prostaglandin EP receptors on cervical and uterine smooth muscle tissue. This binding promotes biochemical changes in the cervical connective tissue matrix (collagen breakdown and increased tissue hydration) that lead to softening, thinning (effacement), and dilation of the cervix, and simultaneously stimulates coordinated, rhythmic contractions of the myometrium similar to those of spontaneous labor. Dinoprostone also increases myometrial responsiveness to subsequently administered oxytocin, which is why the two agents are used sequentially rather than simultaneously in labor induction protocols.

Proston has no pediatric indication. It is used exclusively in pregnant women of reproductive age for cervical ripening, labor induction, or uterine evacuation; safety and efficacy in the pediatric population are not applicable and have not been studied.